Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

被引：2

作者：

Kumar, Shaji ^{[1
]}

Grzasko, Norbert ^{[2
]}

Delimpasi, Sosana ^{[3
]}

Jedrzejczak, Wieslaw W. ^{[4
]}

Grosicki, Sebastian ^{[5
]}

Kyrtsonis, Marie-Christine ^{[6
]}

Spencer, Andrew ^{[7
]}

Gupta, Neeraj ^{[8
]}

Teng, Zhaoyang ^{[9
]}

Byrne, Catriona ^{[9
]}

Labotka, Richard ^{[9
]}

Dimopoulos, Meletios A. ^{[10
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN USA

[2] St Johns Canc Ctr, Dept Hematol, Lublin, Poland

[3] Evangelismos Med Ctr, Dept Hematol, Athens, Greece

[4] Med Univ Warsaw, Dept Hematol & Oncol, MTZ Clin Res, Warsaw, Poland

[5] Med Univ Silesian, Dept Canc Prevent, Katowice, Poland

[6] Laikon Univ Hosp, Dept Propaedeut Internal Med 1, Hematol Sect, Athens, Greece

[7] MONASH Univ, Malignant Haematol & Stem Cell Transplantat Serv, Alfred Hosp, Australian Ctr Blood Dis, Melbourne, Australia

[8] Millennium Pharmaceut Inc, Cambridge, MA USA

[9] Millennium Pharmaceut Inc, Cambridge, MA USA

[10] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

来源：

关键词：

D O I：

10.1182/blood.V128.22.3327.3327

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3327

引用

页数：13